LANCASTER, Pa. (WHTM) Over the weekend, Patients R Waiting held its 4th Annual Diversity in Medicine Conference. The three-day event involved virtual seminars, a blood drive, and CPR training. The goal of the conference is to prepare underrepresented students for careers in medicine.

There are approximately 90,000 excess deaths in the U.S. each year due to health disparities, says Dr. Cherise Hamblin, founder of Patients R Waiting and OB-GYN physician at Lancaster General Penn Medicine.

The study What If We Were Equal? A Comparison Of The Black-White Mortality Gap In 1960 And 2000 found that an estimated 83,570 excess deaths each year could be prevented in the United States if [the] black-white mortality gap could be eliminated.

It is a public health crisis, Hamblin says.

Dr. Sharee Livingston, OB-GYN physician at UPMC Lititz and Patients R Waiting board member, explains that education and access to health care are just two factors that contribute to health disparities. She also noted that implicit bias could additionally affect how medical workers treat their patients.

Patients R Waiting is attempting to address such disparities by increasing diversity in the medical field.

A 2018 study found that Black male patients were more likely to opt for preventative care measures after meeting with a doctor of the same race. Communication between Black doctors and Black patients also appeared to be better than communication between non-Black doctors and Black patients.

Patients are likely to be more compliant if they can identify with the person whos giving them the advice. If you sound like them, you look like them, you have a particular understanding, says Livingston.

Diversity in medicine saves lives, Hamblin says.

About 13% of the U.S. population is Black. However, in 2016, only 7% of physicians identified as Black, Livingston said, citing a USA Today article.

Patients R Waiting is working to increase that percentage by increasing the pipeline of minority clinicians, making that pipeline less leaky, and supporting minority clinicians in practice, says Hamblin.

Becoming a physician has to start with having a desire to do it or thinking that its possible, explains Hamblin. This is where increasing the pipeline of minority clinicians begins by showing younger students their options for working in the medical field.

After students are interested in entering health care professions, Patients R Waiting works to support them through their schooling (making the pipeline less leaky) and continues supporting them after theyve entered the field.

This years Diversity in Medicine (DIM) Conference was directed toward high school and college students working toward jobs in health care. It included several virtual seminars, as well as a blood drive and a day of CPR and STOP THE BLEED training. In addition, the conference included a diversity, equity, and inclusion seminar for educators.

Originally, the conference was supposed to be a weekend-long, in-person event hosted by Franklin & Marshall College, but as COVID-19 restrictions limited gatherings, Dr. Hamblin and Dr. Livingston had to make new plans.

The conference became a combination of small in-person events and virtual seminars. As F&Ms campus was closed to visitors, UPMC Lititz became the new host site.

Livingston says the new format enabled the conference to reach a national audience; over 300 people registered for conference events. Future DIM Conferences may continue as a combination of virtual and in-person programming, says Hamblin.

If you missed the DIM Conference this year, Hamblin says it will be held again next year on the last weekend of September. Patients R Waiting also hosts a What the Health? book club that meets virtually on the last Wednesday of every month and a Bowl-a-thon planned for December.

Editors Note: a study previously included in this article used different methodologies and was removed for clarity.

Visit link:
Diversity in Medicine Conference hopes to bolster number of minority health care workers - ABC27

Renee E. SuttonSeptember 30, 2020

It is hard to believe summer is almost over. September is here and fall is right around the corner. Soon the leaves will be changing and cool crisp air will greet us in the morning. We must not let down our guards when it comes to protecting our skin from the sun. Did you know that an article in JAMA Internal Medicine found that skin cancer is more common than prostate, lung and colon cancer combined?

According to the American Cancer Society, it is likely that there will be over 1,900 new cases of skin cancer in South Carolina this year. You may think you have never known anyone with skin cancer and you may very well be right. However, that does not mean you are less likely to get skin cancer. The National Cancer Institute estimates that in Florence county there will be 48 new cases in 2020.

Risk factors you cannot change include light colored eyes, blonde or red hair, skin that burns or freckles easily or a light skin tone. Also, a family member with skin cancer or being older puts you at higher risk. The good news is that the number one risk factor is under your control: sun exposure. It is true the heat from the sun will be much less in the fall. However, the suns rays will continue to shine and damage our skin. Thankfully, the suns rays can be blocked with the use of sunblock, hats or clothing.

According to the American Journal of Preventative Medicine, one risk factor for skin cancer that you can change is your use of indoor tanning. Tanning exposes you to a high dose of UV rays. The tan you get from a tanning bed is actually skin damage. JAMA Internal Medicine found that tanning beds are the cause of over 10,000 new cases every year. The good news is that spray on tans and home tanning lotions have come a long way. You can now get the same sun-kissed tan without the bad sun rays and cancer risk. Enjoy the coming fall weather, but please dont forget your sunblock or hat the next time you go outside.

More:
Skin Cancer Awareness The Patriot - The Patriot News

As the COVID-19 pandemic continues into the fall, a local doctor is encouraging the community not to wait it out before they return to their doctors office.

Keeping up on routine screenings and annual visits is critically important, and healthcare systems have put precautions in place to keep patients safe as they return to hospitals and clinics, according to Dr. Timothy Gatewood, who specializes in internal medicine at Community Howard Regional Health.

There was a hope when this (COVID-19) started that things would get back to quote-on-quote normal within a few months, but clearly this is going on into the winter. And thats kind of the fear is this gets stretched from months into probably over a year and that the things we need to do on an annual basis are falling out.

"And diseases arent going away; theyre just going undetected, Gatewood said. So were really encouraging people to make sure they continue with their routine healthcare screenings so things are not left undetected or worsen in the absence of detection.

The most important screenings he encouraged people to keep up on fell into two categories. The first category was preventative cancer screenings. Patients still should be getting mammograms, colorectal screenings, prostate cancer screenings, and the like at the recommended ages and increments, he said. The other category was routine health screenings, such as cardiovascular screenings, blood pressure checks, blood sugar monitoring, and cholesterol monitoring at annual visits or routine visits.

In addition, those on medications still should be seeing their physicians for medication monitoring to ensure their underlying conditions are being optimized, Gatewwood said.

At the start of the virus, Community Howard Regional Health's outpatient clinics closed temporarily, and patients transitioned to virtual visits. However, the clinics since have reopened, and Gatewood said many patients have returned to in-person care. Some, however, still are leery of visiting a hospital or doctors office while cases of COVID-19 still are being reported daily.

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by making a contribution.

I think the main concern people have is leaving the house and being around other patients and concern that perhaps theres more prevalence of patients with COVID in the clinic, but the network and probably all healthcare systems have worked hard to triage patients before they come in regarding potential COVID symptoms and to make sure theres not an intermingling of asymptomatic and symptomatic patients, he said.

At Community Howard, like other healthcare networks, systems have been put in place to reduce the spread of COVID-19, including the screening of patients for symptoms of the virus, reduced wait times, reduced seating, increased cleaning and disinfecting measures, and universal mask-wearing.

Mask-wearing, Gatewood said, greatly reduces the risk of transmitting the virus.

The thing that I really try to emphasize to people is how effective mask-wearing is. I think when COVID started it was not clear how effective that was going to be, but as the months have gone by and data has come in, really mask-wearing is critically important, said Gatewood. This is a virus thats spread by the respiratory route, and universal mask-wearing indoors when outside of the home is really the best way that were going to prevent the spread and remain safe. I just think that message has been muddled and confusing, and its unfortunate because I really believe in universal mask-wearing indoors when outside of your immediate bubble is probably the best thing we can do right now to slow or prevent the spread of this.

As flu season is arriving, the doctor also encouraged people to get a flu shot this year, saying it was now more important than ever. The fewer cases of the flu the hospital sees, he said, the better for the patients and the hospital system in general.

Gatewood encouraged people to do what they can to stay healthy while at home, including reducing stressors, getting exercise, and eating healthily.

Gatewood commended the communitys leadership and citizens efforts to prevent the spread of COVID-19.

Its been interesting, but weve learned a lot. Were in a great community Weve had great local leadership, great hospital leadership at both hospitals, and I think the community has done a really good job in handling this because it is a community issue. This is a collective response that everybody shares a part in. So as far as coming in to be seen at the office, the thing I can really emphasize is the providers wear masks. The staff wears masks. All the patients and/or family members in the office wear masks, and that provides a safe environment, Gatewood said.

Continue reading here:
Stay on top of preventative care during pandemic - Kokomo Perspective

The covid-19 pandemic must serve as a wake-up call

It is now clear that global and national preparedness and response to the covid-19 pandemic has been inadequate. Many of the basic principles which underpin public health and wellbeing have been transgressed whether through political hubris, narrowness of vision, or deficiencies in healthcare education.

With the exception of tropical medicine, human medicine in affluent societies in the last 50 years has given relatively little priority, for understandable reasons, to infectious disease. The emergence of HIV and the challenge of antimicrobial resistance have driven some reconsideration in recent years. Nevertheless, the focus in both training and practice has been dominated by the challenges presented by non-communicable diseases in individuals. By contrast, in veterinary medicine infectious diseases have always been of great significance andthe accumulated experience of handling infections in populations of animals can contribute greatly to human pandemic infection control.

The 2015-30 Sustainable Development Goals, ratified by 193 nations, recognised the value of an integrated and ethical approach to society and the environment. From a healthcare perspective, they emphasised the importance of a One Health approach which embraces human, animal, and environmental health and appreciates their critical interdependence. Recent pandemics (e.g. SARS, MERS, 2009 H1N1 influenza, covid-19) emphasise the need for us all to prepare and respond more effectively to the spillover of infections from animals to humans as well as the challenges posed by our degradation of the natural world. The economic benefits of this approach amply justify the costs involved. [1]

The deleterious consequences of infections spilling over between animals to humans are exponentially magnified by the global connectivity of modern times. The covid-19 pandemic had its origins in the natural world, most likely through transmission from bats. Spillover and adaptation to novel host species represents the natural evolutionary trajectory for many viruses (e.g. HIV-1, RSV, measles, common cold coronaviruses). Failure to recognise this reality promotes the risk of similar pandemics in the future. The risk of spillover is increased through our failure to respect the ecological boundaries and habitats of wildlife and our inability to prevent the current accelerating environmental destruction and incursions into wilderness habitats to seek resourceswood, minerals, or clearance for crops and livestock. Trade that brings humans and their livestock into contact with wildlife also increases the risk of spillover.

We suggest that education and training in human and veterinary medicine must more effectively embrace the concept of preventative eco-health whereby the health of all animals (including humans) is protected through preservation of the integrity of the natural world, its services, diversity, and natural ecological barriers. Recent analysis has shown that the cost of preventing further pandemics over the next decade by protecting wildlife and forests equates to just 2% of the estimated financial damage caused by covid-19. [1] Moreover, with shared drivers for disease emergence and, very often, shared pathogens, the human medical and veterinary medical sectors must adopt effective multi-speciality coordination for surveillance and rapid detection (e.g. the UK governments human-animal infections and risk surveillance [HAIRS] group). While efforts to capture the full extent of microbial diversity (e.g. Global Virome Network) are underway, predicting the timing, location and agent of the next epidemic or pandemic remains very challenging. A holistic, more eco-centric, educational and preventative approach, as well as increased governmental and global commitment to pandemic preparedness, should alleviate the most extreme challenges posed by any future pandemic.

The covid-19 pandemic has provided us all with a wake-up call. It has starkly demonstrated the interconnectivity of global healthcare challenges and has led to dramatic changes in societal behaviours and working practices. Widespread global concern over environmental issues will only be assuaged through more effective collaboration in research and practice between medical and veterinary practitioners in partnership with biologists and environmentalists. Education must therefore equip practitioners to function effectively in this new environment. At a time when the worlds biodiversity is facing both a mass extinction event and an increase in emerging infections, professionals in human, animal and environmental health must function as a broader multidisciplinary team. [2] It follows that educational barriers separating human, animal, and environmental health workers should be cast aside in favour of a more integrated training regime. The One Health concept, as advocated by William Osler, Calvin Schwabe, and Lawson Soulsby must be at the foundation of this integrated approach.

Camilla T.O. Benfield, course director, MSc One Health: ecosystems, humans and animals, Royal Veterinary College, London, UK

David Heymann, professor of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

Judy MacArthur Clark, past president, Royal College of Veterinary Surgeons, London, UK

AJ Trees, Lord Trees, House of Lords, London, UK

Babulal Sethia, past president, Royal Society of Medicine, London, UK

The Soulsby Foundation (www.SoulsbyFoundation.org) supports research in One Health through fellowships which enable medical and veterinary professionals, early in their careers, to forge international multidisciplinary collaborations, gain global perspectives, and experience the many cultural contexts of One Health.

Declaration of Interests:The Soulsby Foundation is a charitable incorporated organisation, registered charity number 1174783. CB is director of the joint RVC-LSHTM MSc in One Health course and in receipt of a 2018 Soulsby Fellowship. DLH, JMC, AJT and BS are Trustees of the Soulsby Foundation in receipt of no remuneration.

References:

Originally posted here:
We must take a One Health approach to improve human pandemic infection control - The BMJ - The BMJ

Cloned antibodies that stop the coronavirus from spreading in the body are among promising strategies for averting severe illness from COVID-19 before vaccines arrive, said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

Antibody-based medications, other blood products from recovered patients and antivirals are being investigated as early treatments, Fauci said. The aim is to prevent patients from developing the serious lung damage for which Gilead Sciences Inc.s remdesivir and the anti-inflammatory drug dexamethasone are administered.

We are focusing very heavily now on treatment of early infection and/or prevention of infection, Fauci told the Journal of the American Medical Association in an an interview. And thats the bridge to the vaccine.

Immunization against SARS-CoV-2 could begin in the U.S. in November or December, Fauci said, though it will probably take until at least the third quarter of 2021 for enough Americans to be protected against the pandemic virus to significantly diminish its threat.

Fauci said 100 million doses of vaccine may be produced by December, with all six companies supplying the U.S. slated to have made 700 million doses by next April.

Optimally, wed have an oral antiviral drug you can give to more people earlier in the course of the illness, said Robert Chip Schooley, a professor of medicine at the University of California, San Diego, who is studying more potent versions of an existing antiviral treatment.

Vaccines might not be 100% effective, he said, which is better than nothing, but were still going to have to rely on drugs and behavioral modifications for a long time to come.

Blockbuster studies published by the journal Science on Thursday showed about 14% of critical COVID-19 patients have impaired levels of a substance called interferon that helps orchestrate the bodys defense against viral pathogens.

The finding opens up new strategies for identifying high-risk patients and treating them with interferon infusions or, in some cases, removing interferon-blocking antibodies from their blood in a procedure called plasmapheresis.

Monoclonal antibodies, a product made by cloning an antibody captured from the blood of a patient who recovered from COVID-19, could also be given to high-risk patients in nursing homes as a preventative treatment, Fauci said.

Ely Lilly & Co.s experimental antibody LY-CoV555 showed some hopeful signs in a trial among out-patients, the company said on Sept. 16.

We have some cautious optimism that monoclonal antibodies may be an important therapeutic for early disease, Fauci said Sept. 10 in an online briefing for Massachusetts General Hospital staff. We need something to keep people out of the hospital.

Follow this link:
Early COVID-19 treatments could be bridge to vaccine, Fauci says - Boston Herald

A team of mostly US-based researchers found that women who reported always having irregular menstrual cycles experienced higher mortality rates than women who reported very regular cycles in the same age ranges. The study took into account other potentially influential factors, such as age, weight, lifestyle, contraceptives and family medical history.

The study assessed 79,505 women with no history of cardiovascular disease, cancer or diabetes. The women reported the usual length and regularity of their menstrual cycles at three different points: between the ages of 14 to 17, 18 to 22, and 29 to 46 years. The researchers kept track of their health over a 24-year period.

"This study is a real step forward in closing the data gap that exists in women's health. It raises many interesting research questions and areas of future study," Dr. Jacqueline Maybin, a senior research fellow and consultant gynecologist at the University of Edinburgh's MRC Centre for Reproductive Health, told the Science Media Centre in London.

"These data will encourage future interrogation of menstrual symptoms and pathologies as an indicator of long-term health outcomes and may provide an early opportunity to implement preventative strategies to improve women's health across the lifespan," said Maybin, who wasn't involved in the research.

Irregular and long menstrual cycles have been associated with a higher risk of major chronic diseases including ovarian cancer, coronary heart disease, Type 2 diabetes and mental health problems, the study said.

In particular, the research, which published in the BMJ medical journal Wednesday, found that women who reported that their usual cycle length was 40 days or more at ages 18 to 22 years and 29 to 46 years were more likely to die prematurely -- defined as before the age of 70 -- than women who reported a usual cycle length of 26 to 31 days in the same age ranges.

The links were strongest for deaths related to cardiovascular disease than for cancer or death from other causes.

The authors were from the Harvard T.H. Chan School of Public Health, Harvard Medical School, Michigan State University and Huazhong University of Science and Technology in Wuhan, China.

No cause for alarm

Experts said that women who experience irregular or long menstrual cycles shouldn't be alarmed by the findings of the study. Maybin said it's important to remember that irregular menstruation is likely a symptom, not a diagnosis.

"A specific underlying cause of irregular menstruation may increase the risk of premature death, rather than the irregular bleeding, per se. We already know that women with polycystic ovarian syndrome (PCOS), a leading cause of irregular periods, have an increased risk of diabetes, high blood pressure and cancer of the womb. It is important that women with PCOS speak to their doctor to reduce these risks," she said.

The study was observational and can only establish a correlation, not a causal link, between an irregular or long menstrual cycle and premature death. Other unmeasured factors could have influenced the results.

Maybin noted that the participants in the study were all registered nurses. Shift work, particularly nightshifts, has been shown to have a significant impact on long-term health. Abigail Fraser, a reader in epidemiology at the University of Bristol, said that the study didn't appear to take in account socioeconomic status.

The study had some limitations, since the participants had to rely on their own recall of their menstrual cycles, which may not have been completely accurate, the researchers said.

However, the authors said in a news statement that studies such as this one "represent the strongest evidence possible for this question" because menstrual cycles can't be randomized.

An additional vital sign

Like temperature and pulse rate, it should be used to assess a patient's overall health, and doctors should try to identify abnormal menstrual patterns in adolescence. This new study suggested that this should apply to all women during their reproductive lives.

"The important point illustrated by this study is that menstrual regularity and reproductive health provides a window into overall long term health," said Dr. Adam Balen, a professor of reproductive Medicine at Leeds Teaching Hospitals in the UK and the Royal College of Obstetricians and Gynecologists' spokesperson on reproductive medicine.

"Young women with irregular periods need a thorough assessment not only of their hormones and metabolism but also of their lifestyle so that they can be advised about steps that they can take which might enhance their overall health," said Balen, who wasn't involved in the study.

See the original post here:
Irregular periods linked to a greater risk of an early death, study suggests - CNN

BASKING RIDGE, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial of non-invasive vagal nerve stimulation (nVNS) in mild traumatic brain injury (mTBI) and Post-Traumatic Stress Disorder (PTSD). The trial is being sponsored by the Department of Veterans Affairs (VA) Office of Research and Development at the Atlanta VA Medical Center.

As outlined in the study protocol, the conflicts in Afghanistan and Iraq have resulted in a large number of veterans with both mTBI and PTSD, making these conditions important concerns of the Department of Veterans Affairs.1 Fifteen percent of Iraq and Afghanistan veterans suffer from mTBI resulting from their service,2 while 13% suffer from PTSD.3

The study, which plans to enroll 100 veterans, is designed to assess the clinical and physiological effects of nVNS in patients with mTBI and PTSD. The studys primary outcome measures include assessments of the veterans clinical improvement, several objective measurements of brain activity, and changes in the levels of the inflammatory cytokine interleukin-6 (IL6) in response to stress.

mTBI and PTSD disorders have a high degree of overlap, making diagnostic evaluation complex. It is estimated that up to 56% of mTBI patients have co-morbid PTSD,1, 4 and 18% of veterans of the conflicts in Iraq and Afghanistan present with co-morbid mTBI-PTSD,4, 5 making the co-morbid condition more common than either disorder alone. These veterans have higher PTSD symptom levels, more functional impairment,6 increased suicidal ideation,7 poorer health and cognitive function,8 and more post concussive symptoms4 than veterans with either condition alone.

Dr. Douglas Bremner, Professor of Psychiatry and Behavioral Sciences and Radiology at the Emory University School of Medicine, staff physician at the Atlanta Veterans Clinic General Mental Health Unit at the Atlanta VA Medical Center and primary investigator of the study commented, Veterans with these comorbid conditions represent a major portion of those presenting for treatment for conditions related to service in Iraq and Afghanistan and yet there is no single treatment effective for the full range of cognitive and stress symptoms associated with mTBI-PTSD.9 For these reasons, our focus is on veterans with comorbid mTBI and PTSD as a highly relevant condition which deserves the attention of the VA.

We are very pleased to be selected to participate in this important study, saidPeter Staats, MD, Chief Medical Officer of electroCore. This study builds on recent published work by Dr. Bremner and colleagues that supports the clinical role for nVNS for the treatment of mTBI and PTSD, and we are optimistic that those findings will be further confirmed by the results from this study.

The study is supported by a VA Merit Award. For complete details please see clintrials.gov. (NCT04437498)

References

1.Lew HL, Cifu DX, Crowder T and Hinds SR. National prevalence of traumatic brain injury, posttraumatic stress disorder, and pain diagnoses in OIF/OEF/OND Veterans from 2009 to 2011. J Rehabil Res Dev. 2013;50:xi-xiv.

2.Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC and Castro CA. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. New England Journal of Medicine. 2008;358:453-63.

3.Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI and Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. New England Journal of Medicine. 2004;351:13-22.

4.Bremner JD. PTSD and mild traumatic brain injury. In: J. D. Bremner, ed. Posttraumatic Stress Disorder: From Neurobiology to Treatment Hoboken, N.J.: Wiley-Blackwell; 2016: 321-344.

5.Bryant RA. Mental disorders and traumatic injury. Depress Anxiety. 2011;28:99-102.

6.Ragsdale KA, Neer SM, Beidel DC, Frueh BC and Stout JW. Posttraumatic stress disorder in OEF/OIF veterans with and without traumatic brain injury. J Anxiety Disord. 2013;27:420-6.

7.Wisco BE, Marx BP, Holowka DW, Vasterling JJ, Han SC, Chen MS, Gradus JL, Nock MK, Rosen RC and Keane TM. Traumatic brain injury, PTSD, and current suicidal ideation among Iraq and Afghanistan U.S. veterans. J Trauma Stress. 2014;27:244-8.

8. Zatzick DF, Rivara FP, Jurkovich GJ, Hoge CW, Wang J, Fan MY, Russo J, Trusz SG, Nathens A and Mackenzie EJ. Multisite investigation of traumatic brain injuries, posttraumatic stress disorder, and self-reported health and cognitive impairments. Arch Gen Psychiatry. 2010 Dec;67(12):1291-300

9.Brenner LA, Ivins BJ, Schwab K, Warden D, Nelson LA, Jaffee MS and Terrio H. Traumatic brain injury, posttraumatics stress disorder, and postconcussive symptom reporting among troops returning from Iraq. Journal of Head Trauma Rehabilitation. 2010;25:307-312.

About gammaCoregammaCore(nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared inthe United Statesfor adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in theEuropean Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults. In 2019, NICE published an evidence-based Medical Technology Guidance document recommending the use of gammaCore for cluster headache withinNHSEngland.

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

The United States FDA has authorized use of the gammaCore Sapphire CV device for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive vagus nerve stimulation (VNS) on either side of the patients neck, available under an emergency access mechanism called an EUA.

gammaCore Sapphire CV has neither been cleared nor approved for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive Vagus nerve Stimulation (nVNS) on either side of the patients neck during the Coronavirus Disease 2019 (COVID-19) pandemic.

gammaCore Sapphire CV has been authorized for the above emergency use by FDA under an Emergency Use Authorization.

gammaCore Sapphire CV has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked.

Further information is available at:

Authorization Letter:https://www.fda.gov/media/139967/download

Fact Sheet for Healthcare Providers:https://www.fda.gov/media/139968/download

Fact Sheet for Patients:https://www.fda.gov/media/139969/download

Instructions for gammaCore usehttps://www.fda.gov/media/139970/download

About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The companys current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visitwww.electrocore.com.

Forward-Looking StatementThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the potential for nVNS to treat mild traumatic brain injury and Post-Traumatic Stress Disorder, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCores business, sales and marketing, and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to successfully commercialize gammaCore, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with theSECavailable atwww.sec.gov.

Investors:Hans VitzthumLifeSci Advisors617-430-7578hans@lifesciadvisors.com

or

Media Contact:Jackie DorskyelectroCore973-290-0097

Link:
electroCore Announces Department of Veterans Affairs Sponsored Study of Non-Invasive Vagal Nerve Stimulation (nVNS) in Mild Traumatic Brain Injury...

Los Angeles, United State, QY Research recently added a research report, Global Medical Wellness Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Medical Wellness market. It highlights the drivers and restraints and sheds light on the undercurrents defining the threats and opportunities. The research report is projected to provide the readers with a thorough evaluation of factors influencing the global Medical Wellness market. To serve the same purpose, analysts have used a SWOT analysis and Porters five forces analysis. These evaluations are supported by unbiased opinions of market experts.

The assessment of the global Medical Wellness market is determined with mention of global figures and CAGR for the forecast period. Analysts have also included the historic figures for the mentioned segments and the forecast ones to help the readers understand the progress each part of the global Medical Wellness market will make in the coming years.

Get PDF template of this report:

https://www.qyresearch.com/index/detail/1436640/global-medical-wellness-market

Global Medical Wellness Market: Drivers and Restraints

The thorough evaluation of the global Medical Wellness market includes a complete explanation of the drivers present in the market. Analysts have studied the investments in research and development, the impact of changing economies, and consumer behaviors to ascertain the factors that will drive the overall market. In addition, analysts have also tried to factor in changes in manufacturing activities and industrial operations that will determine the sales of the products in the global Medical Wellness market.

This chapter also explains the possible restraints present in the global Medical Wellness market. It assesses the reasons that could hamper the growth of the market. Analysts have evaluated the rising environmental concerns and fluctuating cost of raw materials that is projected to dampen the spirit of the global Medical Wellness market. However, analysts have also presented potential opportunities that the players in the global Medical Wellness market can bank on. The chapter on drivers, restraints, threats, and opportunities presents a holistic view of the global Medical Wellness market.

Key players cited in the report:

Massage Envy, Steiner Leisure Limited, World Gym, Fitness World, Universal Companies, Beauty Farm, VLCC Wellness Center, Nanjing Zhaohui, Edge Systems LLC, HEALING HOTELS OF THE WORLD, Golds Gym International, Bon Vital, Kaya Skin Clinic, The Body Holiday, Kayco Vivid, Arashiyu Japanese Foot Spa, Enrich Hair & Skin, WTS International, Biologique Recherche, Guardian Lifecare, Healthkart Medical Wellness

Global Medical Wellness Market: Competitive Landscape

Analysts have thoroughly assessed the competitive landscape present in the global Medical Wellness market. The report includes the study of the key players operating in the Medical Wellness market. It also details the strategic initiatives that the companies have taken in recent years to keep up with the intensifying competition. In addition, it also includes an evaluation of the financial outlook of these companies, their research and development plans, and their business strategies going forward.

Global Medical Wellness Market: Segment Analysis

This chapter focuses on the various segments present in the global Medical Wellness market. The report segments the market based on type, application, product, service, and end users. This breakdown allows a granular view of the subject. It helps in understanding the changes in production and overall needs of consumers that are likely to influence these segments.

Global Medical Wellness Market by Type Segments:

, Complementary and Alternative Medicine, Beauty Care and Anti-Aging, Preventative & Personalized Medicine and Public Health, Healthy Eating, Nutrition & Weight Loss, Rejuvenation, Other Medical Wellness

Global Medical Wellness Market by Application Segments:

, Franchise, Company Owned Outlets

Global Medical Wellness Market: Regional Analysis

The chapter on regional analysis highlights the political scenario in emerging economies and developed nations that are expected to influence the demand and supply dynamics. The regional analysis also helps in ascertaining the shifting needs of the population that have a critical impact on the overall Medical Wellness market. Cost of labor, raw materials, and production costs depending on the region have also been factored in this part of the research report.

Enquire Customization In the Report:

https://www.qyresearch.com/customize-request/form/1436640/global-medical-wellness-market

Key Questions Answered

The report answers important questions that companies may have when operating in the global Medical Wellness market. Some of the questions are given below:

Answering such types of questions can be very helpful for players to clear their doubts when implementing their strategies to gain growth in the global Medical Wellness market. The report offers a transparent picture of the real situation of the global Medical Wellness market so that companies can operate more effectively. It can be customized according to the needs of readers for better understanding of the global Medical Wellness market.

Table of Content

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Medical Wellness Revenue1.4 Market Analysis by Type1.4.1 Global Medical Wellness Market Size Growth Rate by Type: 2020 VS 20261.4.2 Complementary and Alternative Medicine1.4.3 Beauty Care and Anti-Aging1.4.4 Preventative & Personalized Medicine and Public Health1.4.5 Healthy Eating, Nutrition & Weight Loss1.4.6 Rejuvenation1.4.7 Other1.5 Market by Application1.5.1 Global Medical Wellness Market Share by Application: 2020 VS 20261.5.2 Franchise1.5.3 Company Owned Outlets1.6 Coronavirus Disease 2019 (Covid-19): Medical Wellness Industry Impact1.6.1 How the Covid-19 is Affecting the Medical Wellness Industry

1.6.1.1 Medical Wellness Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Medical Wellness Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Medical Wellness Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Medical Wellness Market Perspective (2015-2026)2.2 Medical Wellness Growth Trends by Regions2.2.1 Medical Wellness Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Medical Wellness Historic Market Share by Regions (2015-2020)2.2.3 Medical Wellness Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Medical Wellness Market Growth Strategy2.3.6 Primary Interviews with Key Medical Wellness Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Medical Wellness Players by Market Size3.1.1 Global Top Medical Wellness Players by Revenue (2015-2020)3.1.2 Global Medical Wellness Revenue Market Share by Players (2015-2020)3.1.3 Global Medical Wellness Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Medical Wellness Market Concentration Ratio3.2.1 Global Medical Wellness Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Medical Wellness Revenue in 20193.3 Medical Wellness Key Players Head office and Area Served3.4 Key Players Medical Wellness Product Solution and Service3.5 Date of Enter into Medical Wellness Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Medical Wellness Historic Market Size by Type (2015-2020)4.2 Global Medical Wellness Forecasted Market Size by Type (2021-2026) 5 Medical Wellness Breakdown Data by Application (2015-2026)5.1 Global Medical Wellness Market Size by Application (2015-2020)5.2 Global Medical Wellness Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Medical Wellness Market Size (2015-2020)6.2 Medical Wellness Key Players in North America (2019-2020)6.3 North America Medical Wellness Market Size by Type (2015-2020)6.4 North America Medical Wellness Market Size by Application (2015-2020) 7 Europe7.1 Europe Medical Wellness Market Size (2015-2020)7.2 Medical Wellness Key Players in Europe (2019-2020)7.3 Europe Medical Wellness Market Size by Type (2015-2020)7.4 Europe Medical Wellness Market Size by Application (2015-2020) 8 China8.1 China Medical Wellness Market Size (2015-2020)8.2 Medical Wellness Key Players in China (2019-2020)8.3 China Medical Wellness Market Size by Type (2015-2020)8.4 China Medical Wellness Market Size by Application (2015-2020) 9 Japan9.1 Japan Medical Wellness Market Size (2015-2020)9.2 Medical Wellness Key Players in Japan (2019-2020)9.3 Japan Medical Wellness Market Size by Type (2015-2020)9.4 Japan Medical Wellness Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Medical Wellness Market Size (2015-2020)10.2 Medical Wellness Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Medical Wellness Market Size by Type (2015-2020)10.4 Southeast Asia Medical Wellness Market Size by Application (2015-2020) 11 India11.1 India Medical Wellness Market Size (2015-2020)11.2 Medical Wellness Key Players in India (2019-2020)11.3 India Medical Wellness Market Size by Type (2015-2020)11.4 India Medical Wellness Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Medical Wellness Market Size (2015-2020)12.2 Medical Wellness Key Players in Central & South America (2019-2020)12.3 Central & South America Medical Wellness Market Size by Type (2015-2020)12.4 Central & South America Medical Wellness Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Massage Envy13.1.1 Massage Envy Company Details13.1.2 Massage Envy Business Overview and Its Total Revenue13.1.3 Massage Envy Medical Wellness Introduction13.1.4 Massage Envy Revenue in Medical Wellness Business (2015-2020))13.1.5 Massage Envy Recent Development13.2 Steiner Leisure Limited13.2.1 Steiner Leisure Limited Company Details13.2.2 Steiner Leisure Limited Business Overview and Its Total Revenue13.2.3 Steiner Leisure Limited Medical Wellness Introduction13.2.4 Steiner Leisure Limited Revenue in Medical Wellness Business (2015-2020)13.2.5 Steiner Leisure Limited Recent Development13.3 World Gym13.3.1 World Gym Company Details13.3.2 World Gym Business Overview and Its Total Revenue13.3.3 World Gym Medical Wellness Introduction13.3.4 World Gym Revenue in Medical Wellness Business (2015-2020)13.3.5 World Gym Recent Development13.4 Fitness World13.4.1 Fitness World Company Details13.4.2 Fitness World Business Overview and Its Total Revenue13.4.3 Fitness World Medical Wellness Introduction13.4.4 Fitness World Revenue in Medical Wellness Business (2015-2020)13.4.5 Fitness World Recent Development13.5 Universal Companies13.5.1 Universal Companies Company Details13.5.2 Universal Companies Business Overview and Its Total Revenue13.5.3 Universal Companies Medical Wellness Introduction13.5.4 Universal Companies Revenue in Medical Wellness Business (2015-2020)13.5.5 Universal Companies Recent Development13.6 Beauty Farm13.6.1 Beauty Farm Company Details13.6.2 Beauty Farm Business Overview and Its Total Revenue13.6.3 Beauty Farm Medical Wellness Introduction13.6.4 Beauty Farm Revenue in Medical Wellness Business (2015-2020)13.6.5 Beauty Farm Recent Development13.7 VLCC Wellness Center13.7.1 VLCC Wellness Center Company Details13.7.2 VLCC Wellness Center Business Overview and Its Total Revenue13.7.3 VLCC Wellness Center Medical Wellness Introduction13.7.4 VLCC Wellness Center Revenue in Medical Wellness Business (2015-2020)13.7.5 VLCC Wellness Center Recent Development13.8 Nanjing Zhaohui13.8.1 Nanjing Zhaohui Company Details13.8.2 Nanjing Zhaohui Business Overview and Its Total Revenue13.8.3 Nanjing Zhaohui Medical Wellness Introduction13.8.4 Nanjing Zhaohui Revenue in Medical Wellness Business (2015-2020)13.8.5 Nanjing Zhaohui Recent Development13.9 Edge Systems LLC13.9.1 Edge Systems LLC Company Details13.9.2 Edge Systems LLC Business Overview and Its Total Revenue13.9.3 Edge Systems LLC Medical Wellness Introduction13.9.4 Edge Systems LLC Revenue in Medical Wellness Business (2015-2020)13.9.5 Edge Systems LLC Recent Development13.10 HEALING HOTELS OF THE WORLD13.10.1 HEALING HOTELS OF THE WORLD Company Details13.10.2 HEALING HOTELS OF THE WORLD Business Overview and Its Total Revenue13.10.3 HEALING HOTELS OF THE WORLD Medical Wellness Introduction13.10.4 HEALING HOTELS OF THE WORLD Revenue in Medical Wellness Business (2015-2020)13.10.5 HEALING HOTELS OF THE WORLD Recent Development13.11 Golds Gym International10.11.1 Golds Gym International Company Details10.11.2 Golds Gym International Business Overview and Its Total Revenue10.11.3 Golds Gym International Medical Wellness Introduction10.11.4 Golds Gym International Revenue in Medical Wellness Business (2015-2020)10.11.5 Golds Gym International Recent Development13.12 Bon Vital10.12.1 Bon Vital Company Details10.12.2 Bon Vital Business Overview and Its Total Revenue10.12.3 Bon Vital Medical Wellness Introduction10.12.4 Bon Vital Revenue in Medical Wellness Business (2015-2020)10.12.5 Bon Vital Recent Development13.13 Kaya Skin Clinic10.13.1 Kaya Skin Clinic Company Details10.13.2 Kaya Skin Clinic Business Overview and Its Total Revenue10.13.3 Kaya Skin Clinic Medical Wellness Introduction10.13.4 Kaya Skin Clinic Revenue in Medical Wellness Business (2015-2020)10.13.5 Kaya Skin Clinic Recent Development13.14 The Body Holiday10.14.1 The Body Holiday Company Details10.14.2 The Body Holiday Business Overview and Its Total Revenue10.14.3 The Body Holiday Medical Wellness Introduction10.14.4 The Body Holiday Revenue in Medical Wellness Business (2015-2020)10.14.5 The Body Holiday Recent Development13.15 Kayco Vivid10.15.1 Kayco Vivid Company Details10.15.2 Kayco Vivid Business Overview and Its Total Revenue10.15.3 Kayco Vivid Medical Wellness Introduction10.15.4 Kayco Vivid Revenue in Medical Wellness Business (2015-2020)10.15.5 Kayco Vivid Recent Development13.16 Arashiyu Japanese Foot Spa10.16.1 Arashiyu Japanese Foot Spa Company Details10.16.2 Arashiyu Japanese Foot Spa Business Overview and Its Total Revenue10.16.3 Arashiyu Japanese Foot Spa Medical Wellness Introduction10.16.4 Arashiyu Japanese Foot Spa Revenue in Medical Wellness Business (2015-2020)10.16.5 Arashiyu Japanese Foot Spa Recent Development13.17 Enrich Hair & Skin10.17.1 Enrich Hair & Skin Company Details10.17.2 Enrich Hair & Skin Business Overview and Its Total Revenue10.17.3 Enrich Hair & Skin Medical Wellness Introduction10.17.4 Enrich Hair & Skin Revenue in Medical Wellness Business (2015-2020)10.17.5 Enrich Hair & Skin Recent Development13.18 WTS International10.18.1 WTS International Company Details10.18.2 WTS International Business Overview and Its Total Revenue10.18.3 WTS International Medical Wellness Introduction10.18.4 WTS International Revenue in Medical Wellness Business (2015-2020)10.18.5 WTS International Recent Development13.19 Biologique Recherche10.19.1 Biologique Recherche Company Details10.19.2 Biologique Recherche Business Overview and Its Total Revenue10.19.3 Biologique Recherche Medical Wellness Introduction10.19.4 Biologique Recherche Revenue in Medical Wellness Business (2015-2020)10.19.5 Biologique Recherche Recent Development13.20 Guardian Lifecare10.20.1 Guardian Lifecare Company Details10.20.2 Guardian Lifecare Business Overview and Its Total Revenue10.20.3 Guardian Lifecare Medical Wellness Introduction10.20.4 Guardian Lifecare Revenue in Medical Wellness Business (2015-2020)10.20.5 Guardian Lifecare Recent Development13.21 Healthkart10.21.1 Healthkart Company Details10.21.2 Healthkart Business Overview and Its Total Revenue10.21.3 Healthkart Medical Wellness Introduction10.21.4 Healthkart Revenue in Medical Wellness Business (2015-2020)10.21.5 Healthkart Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more:
Medical Wellness Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2020-2026(Steiner Leisure Limited, World Gym,...

THURSDAY, Oct. 1, 2020 (HealthDay News) -- In a finding that suggests a woman's periods might be a powerful indicator of her general health, researchers report that women with irregular and long menstrual cycles face a higher risk of early death.

In a study that spanned 24 years and included more than 79,000 premenopausal women who had no history of heart disease, cancer or diabetes, those who'd always had irregular menstrual cycles were more likely to die before the age of 70 than those who had regular cycles.

"The important point illustrated by this study is that menstrual regularity and reproductive health provides a window into overall long-term health," Dr. Adam Balen, a professor of reproductive medicine at Leeds Teaching Hospitals in Britain, told CNN.

"Young women with irregular periods need a thorough assessment, not only of their hormones and metabolism but also of their lifestyle so that they can be advised about steps that they can take which might enhance their overall health," said Balen, who wasn't involved in the study.

Women who had a usual cycle length of 40 days or more at ages 18-22 and 29-46 were more likely to die prematurely than those who had a usual cycle length of 26-31 days in the same age ranges.

These associations were strongest for deaths from heart disease, compared to cancer or other causes. The increased risk was also slightly stronger among smokers, according to the study published Sept. 30 in the BMJ medical journal.

The findings suggest that a woman's menstrual cycle should be considered an important sign of general health throughout her childbearing years, the researchers said in a journal news release. They were led by Jorge Chavarro, from the Harvard T.H. Chan School of Public Health in Boston.

They said the associations between long and irregular menstrual cycles and increased risk of premature death are likely due to hormone disruptions. But the study did not prove that irregular periods actually caused early death, just that there was an association.

Irregular and long menstrual cycles are common among women of reproductive age and have been linked with a higher risk of major chronic diseases including ovarian cancer, heart disease, type 2 diabetes, and mental health problems.

However, there's been little previous evidence to link irregular or long menstrual cycles with early death risk.

"These data will encourage future interrogation of menstrual symptoms and pathologies as an indicator of long-term health outcomes and may provide an early opportunity to implement preventative strategies to improve women's health across the life span," Dr. Jacqueline Maybin told the Science Media Centre in London, CNN reported. She is a senior research fellow and consultant gynecologist at the University of Edinburgh's MRC Centre for Reproductive Health.

"A specific underlying cause of irregular menstruation may increase the risk of premature death, rather than the irregular bleeding, per se," said Maybin, who was not involved in the research. "We already know that women with polycystic ovarian syndrome [PCOS], a leading cause of irregular periods, have an increased risk of diabetes, high blood pressure and cancer of the womb. It is important that women with PCOS speak to their doctor to reduce these risks."

More information

The U.S. National Institute of Child Health and Human Development has more on menstrual irregularities.

SOURCES: BMJ, news release, Sept. 30, 2020; CNN

See the original post:
Irregular, Long Periods Tied to Shorter Life Span - HealthDay News

ITP program providing reimbursement for gammaCore extended to March. 31, 2021 with option for additional three years

The potential contract value if the three-year extension option is exercised could be up to approximately 3.6 million (or approximately $4.6 million based on the current exchange rate)

BASKING RIDGE, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Englands National Health Service (NHS) has extended the Innovation and Technology Payment (ITP) Program for the use of gammaCore for the treatment of cluster headache in adults for an additional six months. The extension will run throughMarch 2021 and via this program, which started inApril 2019, gammaCore will continue to be reimbursed for those patients inEngland who suffer from cluster headache and respond to the therapy. The proposed contract includes the option to extend for up to an additional three years through March 31, 2024. The potential contract value if the three-year extension option is exercised could be up to approximately 3.6 million (or approximately $4.6 million based on the current exchange rate). The award notice can be found here.

The extension ofNHSEnglands ITP program will ensure that our established patient base can continue to access a treatment proven to work for them, whilst also supporting the further adoption of gammaCore in new patients suffering from cluster headache, who are yet to experience the therapy, saidIain Strickland, electroCores VP of European Operations. Importantly, gammaCore remains the only device approved by theNational Institute for Health and Care Excellence(NICE) for use in patients with drug resistant cluster headaches, fulfilling an important unmet need.

The ITP Program is designed to support the adoption of innovations and technologies in theNHSmarket through the removal of significant financial barriers for both NHS commissioners and providers. The program provides funding to these innovative medical technologies and promotes a broader set of activities with Academic Health Science Networks in order to deliver improvements in the quality and efficacy of patient care.

About gammaCore

gammaCore (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults. In 2019, NICE published an evidence-based Medical Technology Guidance document recommending the use of gammaCore for cluster headache within NHS England.

Safety and efficacy of gammaCore have not been evaluated in the following patients:

Patients should not use gammaCore if they:

For additional safety information please see Instruction for Use here.

In the United States, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing gammaCore.

The United States FDA issued an Emergency Use Authorization (EUA) for acute use of the gammaCore Sapphire CV device at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive vagus nerve stimulation (nVNS) on either side of the patients neck, available under an emergency access mechanism called an EUA.

gammaCore Sapphire CV has neither been cleared nor approved for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive vagus nerve stimulation (nVNS) on either side of the patients neck during the Coronavirus Disease 2019 (COVID-19) pandemic.

gammaCore Sapphire CV has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked.

Further information is available at:

Authorization Letter: https://www.fda.gov/media/139967/download

Fact Sheet for Healthcare Providers: https://www.fda.gov/media/139968/download

Fact Sheet for Patients: https://www.fda.gov/media/139969/download

Instructions for gammaCore use https://www.fda.gov/media/139970/download

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The companys initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visitwww.electrocore.com.

Forward-Looking Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about anticipated government funding arrangements provided by the NHS and NICE, electroCore's business prospects, sales and marketing, and product development plans, future cash flow projections, anticipated costs, its pipeline or potential markets for its technologies, the availability and impact of payer coverage, the potential product use for other indications, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCores business, sales and marketing, and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to successfully commercialize gammaCore, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with theSECavailable atwww.sec.gov.

Investors:Hans VitzthumLifeSci Advisors617-430-7578hans@lifesciadvisors.com

or

Media Contact:Jackie DorskyelectroCore973-290-0097

View original post here:
electroCore, Inc. Announces Extension of NHS England's Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore in England -...